The International Journal of Neuropsychopharmacology
September 9, 2026
Claudio Agnorelli, Joseph Peill, Danielle Kurtin et al.
Abstract Background Clinical studies have shown that ketamine and classic psychedelics can produce robust and rapid antidepressant effects after a single or a few administrations. However, the neurobiological mechanisms driving these long-lasting changes remain unclear. A leading framework proposes that both drug classes induce sustained increases in neuroplasticity, potentially reshaping...
The International Journal of Neuropsychopharmacology
September 9, 2026
B Richardson, J O'Byrne, V Bruno et al.
Abstract Background Psychedelics induce altered states of consciousness (AOC) with profound perceptual, cognitive, and emotional shifts, often linked to positive therapeutic outcomes. Although serotonergic psychedelics such as psilocybin, LSD, and 5-MeO-DMT share receptor targets, they differ in behavioral and neural effects. How these compounds alter cortical dynamics relative to other...
The International Journal of Neuropsychopharmacology
September 9, 2026
J Ramaekers
Abstract Background Short-acting psychedelics such as 5-MeO-DMT and DMT may induce rapid relief of depressive symptoms after brief but intense psychedelic experiences. Aims & Objectives This presentation examines their clinical pharmacology and therapeutic potential in depression. Method Review of clinical data. Results Both compounds primarily target serotonergic receptors, notably 5-HT1A and...
Brain Research
September 7, 2026
Eleni Kroupi, Helena Araujo, Cas Oosterveld et al.
N,N-Dimethyltryptamine (DMT), a potent serotonin-2A receptor agonist, elicits intense psychedelic experiences and has become a focus of interest in neuroscience and mental health research. While EEG studies of psychedelics typically report reduced alpha power, increased delta power, and enhanced signal complexity-primarily assessed using Lempel-Ziv complexity (LZc)-less is known about DMT's...
Canadian Journal of Chemistry
September 4, 2026
Anton A. Homon, Pavithra Prasad, Jaxon Laramie et al.
The recent resurgence in psychedelic research has increased demand for these molecules for clinical studies. Due to the differences between national regulations and considering the dominance of the American market and its continued prohibition of many such molecules, the commercial availability of many of these compounds remains poor. This has also inhibited research into developing scalable...
The International Journal of Neuropsychopharmacology
September 1, 2026
Bernhard T Baune, T. Benway, D. Gregory et al.
Abstract Background Treatment-resistant depression (TRD) is a chronic condition affecting approximately 30% of patients with major depressive disorder, posing a significant unmet need for safe and effective treatments. GH001, an inhaled formulation of mebufotenin (5-MeO-DMT), has shown good tolerability and safety in early stage clinical trials in healthy volunteers and patients with TRD. Aims...
The International Journal of Neuropsychopharmacology
September 1, 2026
W. Cubała, Kelly Doolin, Fiona Ryan et al.
Abstract Background Treatment-resistant depression (TRD) represents a particularly challenging form of major depressive disorder (MDD), defined by an inadequate response to at least two antidepressants given at adequate dose and duration within the current depressive episode. TRD affects nearly one-third of individuals with MDD and is consistently linked to greater psychiatric and medical...
ACS Pharmacology & Translational Science
August 18, 2026
Richard A Glennon, Maƚgorzata Dukat
Abstract Isotryptamines, or 2-(1-indolyl)ethylamines, are positional or geometric isomers of tryptamines where the aminoethyl substituent has been relocated from the indole 3-position to the N1-position. Early studies with these types of agents relied on peripheral tissue assays for examination of their serotonin (5-hydroxytryptamine; 5-HT) receptor affinities to investigate structure–affinity...
International Journal For Multidisciplinary Research
August 16, 2026
Eric P. Rubenstein
Ayahuasca is traditionally prepared by aqueous extraction and concentration of Banisteriopsis caapi and Psychotria viridis. The resulting beverage contains N,N-dimethyltryptamine (DMT), harmine, harmaline, tetrahydroharmine (THH), additional alkaloids, polyphenolic constituents, carbohydrates, organic acids, suspended solids, and numerous other plant-derived compounds. The source plants are...
The Natural Products Journal
August 12, 2026
Weslany Souza Rocha, João Xavier de Araújo‐Júnior, Edeildo Ferreira da Silva‐Júnior et al.
Introduction: Mimosa tenuiflora (Willd.) Poir., widely known as Jurema preta in Brazil and tepezcohuite in Mexico, is a perennial shrub or tree traditionally used in folk medicine across the Caatinga biome of northeastern Brazil and other regions of Central and South America. Tryptamine is an indole alkaloid naturally found in several species, with M. tenuiflora representing an important...